Essential Amino Acids and Parkinsons Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Parkinson Disease
Interventions
DRUG

AMS2434 (amino acids)

The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.

DRUG

Placebo

Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.

All Listed Sponsors
lead

University of Arkansas

OTHER